This clinical trial is focused on studying the safety of a treatment called efgartigimod alfa in adults with Primary Sjögren’s Syndrome. Primary Sjögren’s Syndrome is an autoimmune disease where the body’s immune system mistakenly attacks its own moisture-producing glands, leading to symptoms like dry mouth and dry eyes. The treatment being tested, efgartigimod alfa, is given as a solution through an intravenous infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of this study is to evaluate the long-term safety of efgartigimod alfa in patients who have completed previous studies involving this treatment. Participants will receive the treatment over a period of 48 weeks. During this time, researchers will monitor the participants’ health closely to identify any side effects or changes in their condition. The study will also track various health indicators, such as laboratory test results and vital signs, to ensure the treatment is safe for long-term use.

Throughout the study, participants will have regular check-ups to assess their response to the treatment. The researchers will look for improvements in disease activity and symptoms, as well as any changes in specific markers in the blood. This information will help determine if efgartigimod alfa is a safe and effective option for managing Primary Sjögren’s Syndrome over an extended period.